Abstract
The COVID-19 pandemic highlighted shortcomings in forecasting models, such as unreliable inputs/outputs and poor performance at critical points. As COVID-19 remains a threat, it is imperative to improve current forecasting approaches by incorporating reliable data and alternative forecasting targets to better inform decision-makers.
Wastewater-based epidemiology (WBE) has emerged as a viable method to track COVID-19 transmission, offering a more reliable metric than reported cases for forecasting critical outcomes like hospitalizations. Recognizing the natural alignment of wastewater systems with city structures, ideal for leveraging WBE data, this study introduces a multi-city, wastewater-based forecasting model to categorically predict COVID-19 hospitalizations.
Using hospitalization and COVID-19 wastewater data for six US cities, accompanied by other epidemiological variables, we develop a Generalized Additive Model (GAM) to generate two categorization types. The Hospitalization Capacity Risk Categorization (HCR) predicts the burden on the healthcare system based on the number of available hospital beds in a city. The Hospitalization Rate Trend (HRT) Categorization predicts the trajectory of this burden based on the growth rate of COVID-19 hospitalizations. Using these categorical thresholds, we create probabilistic forecasts to retrospectively predict the risk and trend category of six cities over a 20-month period for 1, 2, and 3 week forecasting windows.
We also propose a new methodology to measure forecasting model performance at change points, or time periods where sudden changes in outbreak dynamics occurred. We also explore the influence of wastewater as a predictor for hospitalizations, showing its inclusion positively impacts the model’s performance. With this categorical forecasting study, we are able to predict hospital capacity risk and disease trends in a novel and useful way, giving city decision-makers a new tool to predict COVID-19 hospitalizations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by NSF RAPID Award ID 2333435.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced are available online
